- Home
- NUVL vs CUZ Comparison
NUVL vs CUZ Comparison
Compare NUVL & CUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- CUZ
- Stock Information
- Founded
- NUVL 2017
- CUZ 1958
- Country
- NUVL United States
- CUZ United States
- Employees
- NUVL N/A
- CUZ N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- CUZ Real Estate Investment Trusts
- Sector
- NUVL Health Care
- CUZ Real Estate
- Exchange
- NUVL Nasdaq
- CUZ Nasdaq
- Market Cap
- NUVL 5.4B
- CUZ 4.7B
- IPO Year
- NUVL 2021
- CUZ N/A
- Fundamental
- Price
- NUVL $80.48
- CUZ $29.72
- Analyst Decision
- NUVL Strong Buy
- CUZ Buy
- Analyst Count
- NUVL 10
- CUZ 9
- Target Price
- NUVL $119.60
- CUZ $32.00
- AVG Volume (30 Days)
- NUVL 582.7K
- CUZ 1.7M
- Earning Date
- NUVL 08-07-2025
- CUZ 07-31-2025
- Dividend Yield
- NUVL N/A
- CUZ 4.31%
- EPS Growth
- NUVL N/A
- CUZ N/A
- EPS
- NUVL N/A
- CUZ 0.34
- Revenue
- NUVL N/A
- CUZ $892,818,000.00
- Revenue This Year
- NUVL N/A
- CUZ $13.49
- Revenue Next Year
- NUVL N/A
- CUZ $4.42
- P/E Ratio
- NUVL N/A
- CUZ $87.68
- Revenue Growth
- NUVL N/A
- CUZ 10.04
- 52 Week Low
- NUVL $55.54
- CUZ $22.33
- 52 Week High
- NUVL $113.51
- CUZ $32.55
- Technical
- Relative Strength Index (RSI)
- NUVL 59.85
- CUZ 52.86
- Support Level
- NUVL $76.27
- CUZ $29.26
- Resistance Level
- NUVL $80.90
- CUZ $30.57
- Average True Range (ATR)
- NUVL 2.55
- CUZ 0.61
- MACD
- NUVL 0.19
- CUZ -0.14
- Stochastic Oscillator
- NUVL 81.61
- CUZ 29.87
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About CUZ Cousins Properties Incorporated
Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.